Natera, Inc. ($NTRA) Stock Forecast: Up 5.1% Today

What is Natera, Inc.?

Natera (NTRA) is a company specializing in genetic testing services, including minimal residual disease (MRD) testing and noninvasive prenatal testing (NIPT). The stock had a bullish movement today.

Why is Natera, Inc. going up?

NTRA stock is up 5.1% on Apr 17, 2026 18:21

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera (NTRA) Tops Q4 Earnings and Revenue Estimates

Natera (NTRA) reported strong fourth-quarter results, surpassing Zacks Consensus Estimates for both earnings and revenue. The company posted earnings of $0.35 per share, significantly beating the estimated loss of $0.46, and revenues of $665.5 million, exceeding expectations by 0.76%. Despite this positive performance, Natera currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revision trends ahead of the earnings release.

https://www.easternprogress.com/natera-ntra-tops-q4-earnings-and-revenue-estimates/article_b66957c5-478d-5d50-a67b-78c4a51947e2.html

Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance?

This article evaluates Natera's (NTRA) share price performance using discounted cash flow (DCF) and price-to-sales (P/S) analyses. While the DCF model suggests the stock is undervalued by 31.0%, the P/S ratio indicates it is overvalued compared to its fair ratio. The article also presents "Narratives" from different analysts, outlining both bull and bear cases for Natera's future valuation and growth prospects.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-it-time-to-reassess-natera-ntra-after-its-mixed-share-pri

William Blair initiates coverage of Natera (NTRA) with outperform recommendation

William Blair has initiated coverage of Natera (NTRA) with an "outperform" recommendation. This analyst rating suggests that William Blair expects Natera's stock to perform better than the broader market or its industry peers. The initiation of coverage by a prominent firm like William Blair could draw increased attention to Natera from investors.

https://www.msn.com/en-us/money/top-stocks/william-blair-initiates-coverage-of-natera-ntra-with-outperform-recommendation/ar-AA20VjfX?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Natera announced positive interim futility analysis from Allogene Therapeutics’ ALPHA3 trial for cema-cel, an investigational CAR T therapy for large B-cell lymphoma (LBCL). The study uses Natera's CLARITY™ MRD assay to identify high-risk patients, revealing that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance and showed a significant reduction in plasma ctDNA levels compared to the observation arm. These results suggest cema-cel could prevent or delay relapse in LBCL patients with residual disease after initial therapy.

https://www.biospace.com/press-releases/natera-highlights-positive-interim-futility-analysis-from-allogene-therapeutics-mrd-guided-alpha3-trial-in-large-b-cell-lymphoma

Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst

William Blair initiated coverage on Natera (NASDAQ: NTRA), emphasizing the company's strong position in the growing minimal residual disease (MRD) testing market, estimated at over $20 billion. Analyst Andrew Brackmann projects Natera's MRD revenue, estimated at nearly $1 billion in 2025, to grow over 40% in 2026 and potentially fivefold over time. Natera's competitive advantages in clinical evidence, commercial infrastructure, and a diversified multi-segment strategy, including noninvasive prenatal testing (NIPT) and organ health, are expected to ensure long-term growth despite potential new market entrants.

https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51815723/natera-positioned-to-capture-growing-20-billion-mrd-opportunity-analyst

Trending Today

Gasoline ($GASOLINE) Commodity Forecast: Up 7.3% Today

The Boeing Company ($BA) Stock Forecast: Up 5.2% Today

Masco Corporation ($MAS) Stock Forecast: Up 10.5% Today

TE Connectivity Ltd. New Switzerland Registered Shares ($TEL) Stock Forecast: Down 9.3% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.3% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 6.2% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.3% Today

Northrop Grumman Corporation ($NOC) Stock Forecast: Down 5.3% Today

Philip Morris International Inc ($PM) Stock Forecast: Up 6.2% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 7.1% Today

Natera, Inc. Price History

31.02.2026 - NTRA Stock was up 5.1%

• Increased positions by Dakota Wealth Management and DAVENPORT & Co LLC suggest growing institutional interest, which has contributed to the bullish movement.
• Although there is strong institutional ownership, insider selling by CEO Steven Leonard Chapman and others may have caused initial uncertainty among investors.
• Natera's positive Q4 earnings report, surpassing expectations, likely boosted investor confidence and supported the bullish movement.
• Despite being considered undervalued by some estimates, recent share price weakness may have prompted profit-taking and a temporary decrease in the stock price.

31.02.2026 - NTRA Stock was up 6.5%

• Zevenbergen Capital Investments LLC decreased its stake in Natera, Inc. by 18%, while other institutional investors like Dakota Wealth Management and DAVENPORT & Co LLC have shown increased interest, reflecting diverse sentiments within the market.
• The positive development concerning Natera's Signatera™ MRD test aiding older women with breast cancer to avoid surgery likely contributed to the bullish movement, highlighting the company's advanced and impactful technology.
• Despite recent insider selling, including by the CEO, robust quarterly results surpassing expectations have upheld analyst confidence in Natera, with a "Moderate Buy" consensus and an average price target of $253.47, potentially fueling investor confidence and propelling the stock price higher.
• The decline in Natera's shares on March 30 may have been a temporary setback amidst generally positive sentiment, with Wall Street analysts forecasting a substantial upside and maintaining an "Outperform" recommendation, signaling a possible buying opportunity for investors.

01.03.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera Inc. (NTRA) today could be attributed to the positive results from the Signatera molecular residual disease (MRD) test, particularly in identifying breast cancer patients who may avoid surgery, boosting investor confidence in the company's innovative technology.
• Despite the recent share sell-off by Zevenbergen Capital Investments LLC, the overall market sentiment remains positive, with increased interest from other institutional investors and strong quarterly results beating expectations, supporting the stock's upward momentum.
• The study showcasing the efficacy of Signatera in guiding treatment decisions for older women with early-stage breast cancer likely contributed to the stock's bullish movement, as it highlights the potential market expansion and adoption of Natera's testing solutions.

14.03.2026 - NTRA Stock was up 5.1%

• William Blair started covering Natera with an Outperform rating, emphasizing the company's market position and growth prospects, likely boosting investor confidence.
• A favorable interim futility analysis from Allogene Therapeutics' trial utilizing Natera's CLARITY™ MRD assay showed promising results in large B-cell lymphoma, contributing to the positive sentiment surrounding Natera.
• A court ruling ordering a 30% ongoing royalty for Natera in a patent dispute is a significant win, reinforcing the company's intellectual property rights and potentially increasing future revenue.
• Despite a decrease in price, the increase in trading volume after the legal victory indicates investor interest and optimism in Natera's future financial performance, as they anticipate the impact of these events on upcoming earnings.

14.03.2026 - NTRA Stock was up 5.8%

• Today's positive performance by Natera is linked to William Blair's initiation of coverage on the company, endorsing its strong position in diagnostic markets and growth potential.
• The encouraging interim futility analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial, which uses Natera's CLARITY™ MRD assay, also contributed to the optimistic outlook by demonstrating successful MRD clearance in high-risk patients.
• Furthermore, a recent court ruling that mandates a 30% ongoing royalty payment to Natera in a patent dispute is seen as a significant victory for the company, reinforcing its intellectual property rights and hinting at future financial gains.
• Despite concerns such as potential overvaluation and insider sales, Natera's leadership in the market, early-mover advantage, and progress in cancer research are likely bolstering investor confidence in its future growth opportunities.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

16.03.2026 - NTRA Stock was down 6.8%

• The bearish movement in Natera's stock today could be attributed to the mixed evaluations of its share price performance, with conflicting assessments of undervaluation and overvaluation.
• Despite being positioned to capture a significant share of the $20 billion MRD opportunity and receiving an 'Outperform' rating from William Blair, concerns about overvaluation and insider selling may have dampened investor sentiment.
• The positive interim results from Allogene Therapeutics’ ALPHA3 trial, showcasing the effectiveness of cema-cel in reducing MRD levels in lymphoma patients, could have been overshadowed by broader market uncertainties or profit-taking activities.
• Natera's strong growth potential and competitive advantages in the diagnostics sector may still underpin its long-term prospects, despite short-term market fluctuations.

09.03.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock today could be attributed to the Executive Chairman exercising stock options and using shares for taxes. This could have potentially raised concerns among investors about insider activities and the company's financial health.
• Despite Citi maintaining a Buy rating and a target price of $300 for Natera, the market might have reacted negatively to the news of insider selling and the challenges the company faces in profitability.
• The positive sentiment around Natera's upside potential and strong growth of Signatera, as mentioned by billionaire investor Stan Druckenmiller and financial analysts, could be overshadowed by short-term concerns leading to the bearish movement in the stock today.
• Investors will likely keep a close eye on Natera's upcoming earnings and financial performance to gauge its future trajectory, balancing the positive long-term outlook with the immediate challenges the company faces.

12.02.2026 - NTRA Stock was down 5.3%

• The downward movement in NTRA stock recently could be linked to a series of insider selling actions by senior executives, such as the President, CFO, and CEO, causing apprehension among investors regarding the company's future trajectory.
• Despite the positive performance in Q4 earnings, the pessimistic yearly EPS forecast and insider selling transactions might have outweighed the favorable revenue numbers, resulting in reduced investor trust and a subsequent dip in the stock value.
• The recurrent trend of insider sales, even after outperforming analyst estimates, may imply a disconnect between key individuals within the company and market sentiments, fostering uncertainty and contributing to the current bearish sentiment in NTRA stock.

27.02.2026 - NTRA Stock was down 5.1%

• Despite the launch of the Zenith Genomic Assay, Natera (NTRA) witnessed a bearish movement in the market.
• The stock's decline could be related to perceptions of the company being overvalued based on a Price-to-Sales ratio comparison, despite being considered undervalued in a Discounted Cash Flow analysis.
• Insider selling by the CFO and CEO, along with the company's lack of profitability and negative net margin, may have increased investor apprehensions and influenced the market's bearish trend.
• Investors are possibly reevaluating their positions in Natera (NTRA) after the recent downturn, despite the company's solid historical performance and favorable outlook from financial analysts.

10.03.2026 - NTRA Stock was down 5.6%

• The bearish movement in Natera's stock today could be attributed to profit-taking by investors after a recent uptrend following positive legal outcomes.
• The appointment of Director Eric H. Rubin to the insider roster may have raised concerns among investors about potential future decisions or changes within the company.
• Despite the positive rulings in the patent disputes and the increase in royalties, the market may have reacted negatively due to uncertainties surrounding the financial impact on Natera and its competitors.
• The insider activity of the Executive Chairman, Matthew Rabinowitz, exercising stock options and selling shares to cover tax obligations could have also contributed to the downward pressure on the stock price as investors may interpret this as a lack of confidence in the company's future prospects.

10.03.2026 - NTRA Stock was down 7.8%

• The court ruling awarding Natera a 30% royalty on post-injunction revenues from MRD patents against ArcherDx and Invitae was initially seen as a positive development, leading to a slight increase in premarket trading. However, the market may have reacted negatively due to concerns about high cash burn and challenges in clinical trials and reimbursement.
• The addition of director Eric H. Rubin to Natera's insider roster, while providing transparency, did not have a significant impact on the stock movement.
• Despite the favorable court decisions strengthening Natera's intellectual property portfolio, the market may have been influenced by the potential financial implications of the royalty payments on the company's overall performance.
• Analysts revising earnings upwards and the positive influence on stock valuation could indicate long-term growth potential, but the current overvaluation concerns raised in the analysis may have contributed to the bearish market movement.